Minjun Chen received his Ph.D. degree from Zhejiang
University, China, in 2003. Starting in
2003, he worked as an Assistant Professor at the School of Pharmacy at Shanghai
Jiao Tong University in China and was promoted
to Associate Professor in 2005. In 2006, he came to the National Center for Toxicological Research
(NCTR) as a Postdoctoral Fellow jointly with the University of Medicine and
Dentistry of New Jersey. He was promoted to an FDA staff fellow in the division
in 2008 and currently is a staff fellow in the division. He
received the FDA Award for “Outstanding Junior Investigator” in 2012, the NCTR
“Scientific Achievement Award” in 2014, and the FDA “Scientific Achievement
Award for Excellence in Analytical Science” in 2017. He established and
currently co-chairs the FDA Liver Toxicity Working Group (LTWG), which is officially
endorsed by the Office of the Chief Scientist with 60 FDA scientists involved
to gather the expertise of drug-induced liver injury (DILI) within the FDA. His primary research interests encompass
bioinformatics, drug safety, biomarker discovery, and toxicogenomics.
Research Keywords & Expertise
Bioinformatics
Biomarker Discovery
Drug Safety
Toxicogenomics
Drug-Induced Liver Inj...
Fingerprints
53%
Drug-Induced Liver Injury
10%
Toxicogenomics
8%
Drug Safety
7%
Bioinformatics
5%
Biomarker Discovery
Short Biography
Minjun Chen received his Ph.D. degree from Zhejiang
University, China, in 2003. Starting in
2003, he worked as an Assistant Professor at the School of Pharmacy at Shanghai
Jiao Tong University in China and was promoted
to Associate Professor in 2005. In 2006, he came to the National Center for Toxicological Research
(NCTR) as a Postdoctoral Fellow jointly with the University of Medicine and
Dentistry of New Jersey. He was promoted to an FDA staff fellow in the division
in 2008 and currently is a staff fellow in the division. He
received the FDA Award for “Outstanding Junior Investigator” in 2012, the NCTR
“Scientific Achievement Award” in 2014, and the FDA “Scientific Achievement
Award for Excellence in Analytical Science” in 2017. He established and
currently co-chairs the FDA Liver Toxicity Working Group (LTWG), which is officially
endorsed by the Office of the Chief Scientist with 60 FDA scientists involved
to gather the expertise of drug-induced liver injury (DILI) within the FDA. His primary research interests encompass
bioinformatics, drug safety, biomarker discovery, and toxicogenomics.